The US Food and Drug Administration has approved a third tablet therapy to treat a respiratory allergy in less than a month – Ragwitek developed by ALK-Abelló A/S of Denmark and partnered with Merck & Co Inc. ---Subscribe to MedNous to access this article--- Company News Regulation & Policy